佐力藥業(300181.SZ)擬定增募資不超約2.72億元 用於償還銀行借款及補充流動資金
格隆匯3月25日丨佐力藥業(300181.SZ)披露非公開發行股票預案,公司此次非公開發行股票募集資金總額不超過約2.72億元(含2.72億元),在扣除發行費用後,募集資金淨額將用於償還銀行借款及補充流動資金,其中2.3億元用於償還銀行借款,剩餘部分用於補充流動資金。
此次非公開發行的股票數量為6086.2485萬股。此次非公開發行股票的數量以中國證券監督管理委員會最終核准發行的股票數量為準。若公司股票在定價基準日至發行日期間發生除權、除息事項,發行價格、發行數量將進行相應調整。
此次非公開發行股票的發行對象為浙醫健,發行對象以現金方式認購公司此次非公開發行的股份。浙醫健已與公司簽署了附條件生效的《非公開發行股票認購協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.